Recently, the water biopsy database Blood Profiling Atlas, a joint project of 20 famous American academic institutions and drug diagnostic developers, was officially launched. As part of the Cancer Month Program, the project aims to advance the further development of blood analysis and diagnostic techniques.
It is understood that the database will coordinate the collection of circulating tumor cells (CTC), circulating tumor DNA (ctDNA), exogenous body test raw data and selective clinical data from various research institutes and hospitals in the United States and provide them free of charge.
Andrew Gruen, marketing director of Seven Bridges, a member of the project, told reporters, "Our goal is to achieve a large number of clinical data analysis homing and deep mining in the next 45-60 days."
Recently, Seven Bridges, a developer of biomedical data analysis software, is working with the University of Chicago to plan the database portion of the project. The company said it is committed to providing six months of engineering, bioinformatics services and up to $500,000 in computing and storage information to facilitate the development and application of analytics software. Project leader Gruen said, “If we can do this successfully, then we will start a great forward-looking study that truly understands the tens of billions of data we have.â€
The blood samples involved in the project were from AstraZeneca, Eli Lilly, Epic Sciences, Sloan Kettering Cancer Center (MSK), Foundation Medicine, Genentech, Guardant Health, Personal Genome Diagnostics (PGDx), Novartis, Pfizer, etc. 13 companies and research institutions.
MSK (Sloan Kettering Cancer Center) stated that it is willing to share blood sample collection methods, cell-free nucleic acid analysis comparison results for different treatment methods, and CTC data from patients with metastatic prostate cancer. These data will help explain the impact of past treatment effects.
MSK researcher Dr. Scher emphasized: "Prostate cancer is a cancer that is difficult to confirm by biopsy. It does not spread between the tumors, but infiltrates the bone marrow, which makes it difficult to detect. Therefore, we will be based on Epic Sciences. The experimental method further provides CTC characterization data for prostate cancer at the phenotypic and genomic level and is working with Epic on a cell classification method that if cells look similar, they may have similar genetic alterations to achieve classification The purpose of the cell."
RT-PCR Test Reagent Kit Of COVID-19(ORF1ab, N)
The RT-PCR Test Reagent Kit Of COVID-19(ORF1ab, N) is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper and lower respiratory specimens (such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) from individuals suspected of COVID-19 by their healthcare provider.
Results are for the identification of SARS-CoV-2 RNA.The SARS-CoV-2 RNA is generally detectable in upper and lower respiratory specimens during the acute phase of infection.
Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infective status. The agent detected may not be the definite cause of disease. Positive results do not rule out bacterial co-infection with other viruses.
Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. The COVID-19 RT-PCR Detection Kit is intended for use by qualified trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures.
RT-PCR testing reagent kit,RT PCR test reagent,Covid-19 PCR Diagnostic reagent,RT PCR reagent kit,real time PCR test reagent
Shenzhen Uni-medica Technology Co.,Ltd , https://www.unimed-global.com